

Interview Summary	Application No. 09/868,305	Applicant(s) ALBERS ET AL.	
	Examiner Thomas McKenzie Ph.D.	Art Unit 1624	

All participants (applicant, applicant's representative, PTO personnel):

(1) Thomas McKenzie Ph.D. (3) _____

(2) Howard Lee. (4) _____

Date of Interview: 07 April 2004.

Type: a) ☒ Telephonic b) ☐ Video Conference
c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No.
If Yes, brief description: _____

Claim(s) discussed: 35 and 36.

Identification of prior art discussed: none.


Agreement with respect to the claims f) ☐ was reached. g) ☒ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Applicants' argument that claims to inhibiting angiogenesis are found in allowed patents closely related to the present application is persuasive. Thus, the enablement rejection made in point #5 of the final rejection is withdrawn.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.


Examiner's signature, if required

Continuation of 5. does NOT place the application in condition for allowance because: double patenting rejection remains for reasons discussed in previous advisory action .

TCW